Nikhil C. Munshi, MD

Adjunct Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

Publications

  • Published 9/23/2025

    Branagan AR, Mo C, Lei M, Gustine JN, Yee AJ, O'Donnell E, Castillo JJ, Nadeem O, Flynn C, Bernstein Z, Nakamoto-Matsubara R, Meid K, Verma R, Hunter ZR, Guerrera ML, Alter G, Burke J, Harrington C, Agyemang E, Gammon M, Lively K, Packer L, Horick N, Laubach J, Mitsiades CS, Munshi N, Anderson KC, Treon SP, Richardson PG, Raje NS, Sarosiek SR. Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579. PMID: 40472329.

    Read at: PubMed

  • Published 9/19/2025

    Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr JG. The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia. 2025 Sep 19. PMID: 40973768.

    Read at: PubMed

  • Published 9/11/2025

    Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli U, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S. The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma. Blood. 2025 Sep 11; 146(11):1286-1299. PMID: 40300074.

    Read at: PubMed

  • Published 9/1/2025

    La J, Hshieh T, Hamparsumian A, Zwolinski R, Wood J, Dharne M, Gaziano JM, Brophy MT, Do NV, Munshi NC, Driver JA, Abel GA, Fillmore NR, DuMontier C. Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System. J Natl Compr Canc Netw. 2025 Sep; 23(9):363-370. PMID: 40930142.

    Read at: PubMed

  • Published 8/26/2025

    Little JS, Medina Pena A, Kim EB, Yee AJ, Nadeem O, Midha S, Sperling AS, Munshi NC, Raje N, Frigault MJ, Cirstea DD, Hammond SP. Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy. Blood Adv. 2025 Aug 26; 9(16):4190-4194. PMID: 40561525.

    Read at: PubMed